Crystal structure of catena-poly[[[bis­(3-oxo-1,3-di­phenyl­prop-1-enolato-κ(2) O,O′)zinc(II)]-μ(2)-tris­[4-(pyridin-3-yl)phen­yl]amine-κ(2) N:N′] tetra­hydro­furan monosolvate]...

por Kashiwagi, Yukiyasu, Kubono, Koji, Tamai, Toshiyuki
Publicado 2019

Crystal structure of 7,7′-[(pyridin-2-yl)methyl­ene]bis­(5-chloro­quinolin-8-ol)

por Kashiwagi, Yukiyasu, Kubono, Koji, Tamai, Toshiyuki
Publicado 2020

Room-temperature coalescence of Pd nanoparticles with sacrificial templates and sintering agents, and their catalytic activities in the Suzuki coupling reaction

por Okada, Soichiro, Nakahara, Yoshio, Watanabe, Mitsuru, Tamai, Toshiyuki, Kobayashi, Yasuyuki, Yajima, Setsuko
Publicado 2022

Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure–Response Analyses

por Tamai, Toshiyuki, Hayato, Seiichi, Hojo, Seiichiro, Suzuki, Takuya, Okusaka, Takuji, Ikeda, Kenji, Kumada, Hiromitsu
Publicado 2017

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

por Ikeda, Kenji, Kudo, Masatoshi, Kawazoe, Seiji, Osaki, Yukio, Ikeda, Masafumi, Okusaka, Takuji, Tamai, Toshiyuki, Suzuki, Takuya, Hisai, Takashi, Hayato, Seiichi, Okita, Kiwamu, Kumada, Hiromitsu
Publicado 2016

Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies

por Motzer, Robert J., Taylor, Matthew H., Evans, Thomas R. Jeffry, Okusaka, Takuji, Glen, Hilary, Lubiniecki, Gregory M., Dutcus, Corina, Smith, Alan D., Okpara, Chinyere E., Hussein, Ziad, Hayato, Seiichi, Tamai, Toshiyuki, Makker, Vicky
Publicado 2022

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

por Yamashita, Tatsuya, Kudo, Masatoshi, Ikeda, Kenji, Izumi, Namiki, Tateishi, Ryosuke, Ikeda, Masafumi, Aikata, Hiroshi, Kawaguchi, Yasunori, Wada, Yoshiyuki, Numata, Kazushi, Inaba, Yoshitaka, Kuromatsu, Ryoko, Kobayashi, Masahiro, Okusaka, Takuji, Tamai, Toshiyuki, Kitamura, Chifumi, Saito, Kenichi, Haruna, Katsuya, Okita, Kiwamu, Kumada, Hiromitsu
Publicado 2019

Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT

por Okusaka, Takuji, Ikeda, Kenji, Kudo, Masatoshi, Finn, Richard, Qin, Shukui, Han, Kwang-Hyub, Cheng, Ann-Lii, Piscaglia, Fabio, Kobayashi, Masahiro, Sung, Max, Chen, Minshan, Wyrwicz, Lucjan, Yoon, Jung-Hwan, Ren, Zhenggang, Mody, Kalgi, Dutcus, Corina, Tamai, Toshiyuki, Ren, Min, Hayato, Seiichi, Kumada, Hiromitsu
Publicado 2021

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study

por Finn, Richard S., Kudo, Masatoshi, Cheng, Ann-Lii, Wyrwicz, Lucjan, Ngan, Roger K.C., Blanc, Jean-Frederic, Baron, Ari D., Vogel, Arndt, Ikeda, Masafumi, Piscaglia, Fabio, Han, Kwang-Hyub, Qin, Shukui, Minoshima, Yukinori, Kanekiyo, Michio, Ren, Min, Dairiki, Ryo, Tamai, Toshiyuki, Dutcus, Corina E., Ikezawa, Hiroki, Funahashi, Yasuhiro, Evans, Thomas R. Jeffry
Publicado 2021